NEW YORK, May 4, 2011 /PRNewswire/ -- Venture capital (VC) funding in the Life Sciences sector, which includes the Biotechnology and Medical Device industries, recovered in terms of dollar investments during the first quarter of 2011, according to a new PwC US report, "A Case for Cautious Optimism." The report includes data from the PricewaterhouseCoopers LLP/National Venture Capital Association MoneyTree™ Report, based on data from Thomson Reuters.
Venture investment for the Life Sciences sector grew by 7 percent in dollars year over year to $1.4 billion. Deal volume, however, declined 8 percent compared to the first quarter of 2010, dropping to 164 deals in Q1 2011. The quarterly deal count represents the lowest number in a single quarter since the first quarter of 2009.
"The first quarter investment total sets us on a path for a solid level of investing in 2011. While we did see a drop in deal volume, the dollar investment remains strong," noted Tracy T. Lefteroff, global managing partner of the venture capital practice at PwC. "Venture funds are expected to continue being cautious about investing in life sciences as the economic recovery progresses, but their stated interest in the sector is long term. They recognize the potential of an industry that is only beginning to embark on a new era of personalized medicine to deliver more effective and targeted treatments that could improve the health of millions of people in all regions of the world."
During the first quarter of 2011, the share of Biotechnology investments decreased to 57 perce
Copyright©2010 PR Newswire.
All rights reserved